Axsome Therapeutics (FRA:19X) E10: €-3.08 (As of Mar. 2026)


FRA:19X Axsome Therapeutics Inc FRA:19X
52 GF Score
Price €206.20
GF Value €188.06
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Axsome Therapeutics E10?

Axsome Therapeutics FRA:19X -1.72% 52 E10 is €-3.08 as of Mar. 2026. GuruFocus rates FRA:19X with a GF Score™ of 52/100 and a GF Value™ of €188.06 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Axsome Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was €-1.090. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-3.08 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-29), Axsome Therapeutics's current stock price is €206.20. Axsome Therapeutics's E10 for the quarter that ended in Mar. 2026 was €-3.08. Axsome Therapeutics's Shiller PE Ratio of today is .


Axsome Therapeutics  (FRA:19X) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Axsome Therapeutics E10 Related Terms


Axsome Therapeutics E10 Historical Data

* Premium members only.

The historical data trend for Axsome Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Axsome Therapeutics E10 Chart

Axsome Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -2.65 -2.52

Axsome Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.00 -2.92 -2.88 -2.52 -3.08

FRA:19X vs MDGL, IONS, BMRN: E10 Comparison

For the Biotechnology subindustry, Axsome Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axsome Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Axsome Therapeutics's Shiller PE Ratio falls into.


FRA:19X
52GF Score
Axsome Therapeutics Inc FRA:19X
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Axsome Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Axsome Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-1.09/330.2130*330.2130
=-1.090

Current CPI (Mar. 2026) = 330.2130.

Axsome Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201606 -0.320 241.018 -0.438
201609 -0.339 241.428 -0.464
201612 -0.360 241.432 -0.492
201703 -0.383 243.801 -0.519
201706 -0.267 244.955 -0.360
201709 -0.227 246.819 -0.304
201712 -0.262 246.524 -0.351
201803 -0.154 249.554 -0.204
201806 -0.274 251.989 -0.359
201809 -0.266 252.439 -0.348
201812 -0.281 251.233 -0.369
201903 -0.283 254.202 -0.368
201906 -0.363 256.143 -0.468
201909 -0.508 256.759 -0.653
201912 -0.639 256.974 -0.821
202003 -0.796 258.115 -1.018
202006 -0.435 257.797 -0.557
202009 -0.518 260.280 -0.657
202012 -0.641 260.474 -0.813
202103 -0.655 264.877 -0.817
202106 -0.714 271.696 -0.868
202109 -0.791 274.310 -0.952
202112 -0.797 278.802 -0.944
202203 -0.935 287.504 -1.074
202206 -1.003 296.311 -1.118
202209 -1.081 296.808 -1.203
202212 -1.331 296.797 -1.481
202303 -0.243 301.836 -0.266
202306 -1.421 305.109 -1.538
202309 -1.237 307.789 -1.327
202312 -1.907 306.746 -2.053
202403 -1.325 312.332 -1.401
202406 -1.551 314.175 -1.630
202409 -1.207 315.301 -1.264
202412 -1.471 315.605 -1.539
202503 -1.128 319.799 -1.165
202506 -0.841 322.561 -0.861
202509 -0.801 324.800 -0.814
202512 -0.478 324.054 -0.487
202603 -1.090 330.213 -1.090

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-3.08 mean?
Axsome Therapeutics (FRA:19X) has a E10 of €-3.08 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Axsome Therapeutics and its competitors.
Is Axsome Therapeutics' E10 too high?
Axsome Therapeutics' current E10 is €-3.08. Overall, Axsome Therapeutics has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Axsome Therapeutics' E10 compare to MDGL and IONS?
Axsome Therapeutics' E10 of €-3.08 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Axsome Therapeutics and its competitors. Axsome Therapeutics's current E10 is €-3.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axsome Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Axsome Therapeutics (FRA:19X) is currently considered Fairly Valued. The stock's GF Value™ is €188.06, compared to a current price of €206.20 — trading 9.6% above its estimated fair value. The current E10 is €-3.08. Axsome Therapeutics' overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Axsome Therapeutics (FRA:19X), the current E10 is €-3.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Axsome Therapeutics (FRA:19X) Overvalued in 2026?

Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued. The current stock price of €206.20 is trading 9.6% above its estimated GF Value™ of €188.06. GuruFocus considers Axsome Therapeutics to be Fairly Valued.

Key valuation signals for FRA:19X:

  • E10: €-3.08
  • GF Value™: €188.06 vs. price of €206.20 (9.6% above fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the FRA:19X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Axsome Therapeutics Business Description

Address One World Trade Center, 29th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
52GF Score

Get the complete analysis for FRA:19X

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€206.20
Price
€188.06
GF Value